Keros Therapeutics Inc Forecast, price target & analysts
Keros Therapeutics Inc Target price 2026 - Analyst rating & recommendation
Keros Therapeutics Inc Classifications & Recommendation
Keros Therapeutics Inc Price Target
| Target Price | $18.36 |
| Price | $11.55 |
| Potential |
58.96%
register free of charge
|
| Number of Estimates | 7 |
|
7 Analysts have issued a price target Keros Therapeutics Inc 2027 .
The average Keros Therapeutics Inc target price is $18.36.
This is
58.96%
register free of charge
$26.25
127.27%
register free of charge
$16.16
39.91%
register free of charge
|
|
| A rating was issued by 13 analysts: 9 Analysts recommend Keros Therapeutics Inc to buy, 4 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Keros Therapeutics Inc stock has an average upside potential 2027 of
58.96%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 244.06 | 16.46 |
| 6,774.93% | 93.26% | |
| EBITDA Margin | 29.53% | -684.50% |
| 100.50% | 2,417.69% | |
| Net Margin | 35.65% | -680.55% |
| 100.68% | 2,008.92% |
9 Analysts have issued a sales forecast Keros Therapeutics Inc 2026 . The average Keros Therapeutics Inc sales estimate is
This results in the following potential growth metrics:
3 Analysts have issued an Keros Therapeutics Inc EBITDA forecast 2026. The average Keros Therapeutics Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
9 Keros Therapeutics Inc Analysts have issued a net profit forecast 2026. The average Keros Therapeutics Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 2.30 | -5.65 |
| 146.00% | 345.65% | |
| P/E | negative | |
| EV/Sales | negative |
9 Analysts have issued a Keros Therapeutics Inc forecast for earnings per share. The average Keros Therapeutics Inc EPS is
This results in the following potential growth metrics and future valuations:
Keros Therapeutics Inc...
Current Keros Therapeutics Inc Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Wells Fargo |
Locked
➜
Locked
|
Locked | Aug 04 2026 |
| Leerink Partners |
Locked
➜
Locked
|
Locked | Aug 04 2026 |
| Wells Fargo |
Locked
➜
Locked
|
Locked | Mar 05 2026 |
| B of A Securities |
Locked
➜
Locked
|
Locked | Nov 28 2025 |
| Oppenheimer |
Locked
➜
Locked
|
Locked | Nov 12 2025 |
| Wells Fargo |
Locked
➜
Locked
|
Locked | Nov 11 2025 |
| Wedbush |
Locked
➜
Locked
|
Locked | Nov 06 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Wells Fargo:
Locked
➜
Locked
|
Aug 04 2026 |
|
Locked
Leerink Partners:
Locked
➜
Locked
|
Aug 04 2026 |
|
Locked
Wells Fargo:
Locked
➜
Locked
|
Mar 05 2026 |
|
Locked
B of A Securities:
Locked
➜
Locked
|
Nov 28 2025 |
|
Locked
Oppenheimer:
Locked
➜
Locked
|
Nov 12 2025 |
|
Locked
Wells Fargo:
Locked
➜
Locked
|
Nov 11 2025 |
|
Locked
Wedbush:
Locked
➜
Locked
|
Nov 06 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
